Maxime Dely: 4 Criteria for Choosing the Right Leukoreduction Filter
Maxime Dely,ย Sales and Application Specialist in Therapeutic Apheresis and Cell Therapy, has shared a post onย LinkedIn:
“๐๐ผ ๐ฎ๐น๐น ๐น๐ฒ๐๐ธ๐ผ๐ฟ๐ฒ๐ฑ๐๐ฐ๐๐ถ๐ผ๐ป ๐ณ๐ถ๐น๐๐ฒ๐ฟ๐ ๐ฝ๐ฒ๐ฟ๐ณ๐ผ๐ฟ๐บ ๐๐ต๐ฒ ๐๐ฎ๐บ๐ฒ? ๐ก๐ผ๐ ๐ฟ๐ฒ๐ฎ๐น๐น๐โฆ
In transfusion medicine, not all filters are equal. Behind what looks like a simple device lie technical choices that directly ๐ถ๐บ๐ฝ๐ฎ๐ฐ๐ ๐ฝ๐ฎ๐๐ถ๐ฒ๐ป๐ ๐๐ฎ๐ณ๐ฒ๐๐ ๐ฎ๐ป๐ฑ ๐ฏ๐น๐ผ๐ผ๐ฑ ๐ฝ๐ฟ๐ผ๐ฑ๐๐ฐ๐ ๐พ๐๐ฎ๐น๐ถ๐๐. Soโฆ how do you know which one is the right filter?
Here are the 4 key criteria
๐ญ. ๐๐ฒ๐๐ธ๐ผ๐ฟ๐ฒ๐ฑ๐๐ฐ๐๐ถ๐ผ๐ป ๐ฝ๐ฒ๐ฟ๐ณ๐ผ๐ฟ๐บ๐ฎ๐ป๐ฐ๐ฒ
โพ European standard: โค 1 million residual white blood cells
โพ AABB standard: โค 5 million
In practice, users often expect a filter to perform ๐ฑ ๐๐ผ ๐ญ๐ฌ ๐๐ถ๐บ๐ฒ๐ ๐ฏ๐ฒ๐๐๐ฒ๐ฟ ๐๐ต๐ฎ๐ป ๐๐ต๐ฒ๐๐ฒ ๐น๐ถ๐บ๐ถ๐๐, to ensure stability and safety.
๐ฎ. ๐ฅ๐ฒ๐๐ถ๐ฑ๐๐ฎ๐น ๐น๐ผ๐๐๐ฒ๐
An efficient filter retains leukocytesโฆ but it may also trap red blood cells. Too much loss = a direct impact on ๐ต๐ฒ๐บ๐ผ๐ด๐น๐ผ๐ฏ๐ถ๐ป ๐น๐ฒ๐๐ฒ๐น๐, or on the required minimum recovery (โฅ ๐ด๐ฑ% ๐ฎ๐ฐ๐ฐ๐ผ๐ฟ๐ฑ๐ถ๐ป๐ด ๐๐ผ ๐๐๐๐). The challenge is to find the right balance.
๐ฏ. ๐๐ถ๐น๐๐ฟ๐ฎ๐๐ถ๐ผ๐ป ๐๐ฝ๐ฒ๐ฒ๐ฑ
Some centers want ultra-fast processing . Others prefer quality over speed. It all depends on the number of units to process daily and the available โ๐บ๐ฎ๐๐ธ๐ฒ๐ฑ ๐๐ถ๐บ๐ฒ.โ
๐ฐ. ๐๐ถ๐ป๐ฎ๐น ๐ฐ๐ผ๐บ๐ฝ๐ผ๐ป๐ฒ๐ป๐ ๐พ๐๐ฎ๐น๐ถ๐๐
Filters also influence hemolysis in red blood cells or platelet activation in PC. An invisible variableโฆ but one that determines therapeutic value.
Conclusion – there is no such thing as a โ๐ฝ๐ฒ๐ฟ๐ณ๐ฒ๐ฐ๐โ ๐ณ๐ถ๐น๐๐ฒ๐ฟ. The right filter is the one that ๐ณ๐ถ๐๐ ๐๐ผ๐๐ฟ ๐ฝ๐ฟ๐ผ๐ฐ๐ฒ๐๐, ๐๐ผ๐๐ฟ ๐ฝ๐ฟ๐ถ๐ผ๐ฟ๐ถ๐๐ถ๐ฒ๐, ๐ฎ๐ป๐ฑ ๐๐ผ๐๐ฟ ๐ฝ๐ฎ๐๐ถ๐ฒ๐ป๐๐.
๐๐ฏ๐ฅ ๐บ๐ฐ๐ถ, ๐ธ๐ฉ๐ช๐ค๐ฉ ๐ฐ๐ง ๐ต๐ฉ๐ฆ๐ด๐ฆ ๐ค๐ณ๐ช๐ต๐ฆ๐ณ๐ช๐ข ๐ธ๐ฆ๐ช๐จ๐ฉ๐ด ๐ต๐ฉ๐ฆ ๐ฎ๐ฐ๐ด๐ต ๐ช๐ฏ ๐บ๐ฐ๐ถ๐ณ ๐ฅ๐ฆ๐ค๐ช๐ด๐ช๐ฐ๐ฏ๐ด?”
Find similar posts on Hemostasis Today.
-
Sep 29, 2025, 12:54Microfluidic Technology Uncovers Ongoing TTP Disease Activity
-
Sep 29, 2025, 12:43Advancing Thrombosis Research: MRI-Based Methodology for Studying Thrombus Resolution
-
Sep 29, 2025, 05:58Samwel Mikaye on Understanding, Diagnosing, and Managing Deep Venous Thrombosis (DVT)
-
Sep 28, 2025, 14:08Mary Cushman: Dr Warkentin Is a Giant in Hematology
-
Sep 28, 2025, 13:31Michael Makris Highlights Vaccine Misinformation and Its Risks
-
Sep 29, 2025, 12:33Allison Wheeler: Some Days I Love Science a Little Bit More
-
Sep 29, 2025, 06:23Yudi Hardianto and Colleagues Give a Review on Stroke Rehabilitation in LMICs
-
Sep 29, 2025, 04:42Wolfgang Miesbach on the Bi8 Study: A Novel FVIII-Mimetic Antibody Gene Therapy for Haemophilia A
-
Sep 29, 2025, 04:16Salvador Payรกn Pernรญa on Equity Challenges in Access to Gene Therapy for Hemoglobinopathies
-
Sep 29, 2025, 04:02Nicolas Gendron: A Very Nice Demonstration by The Authors - Coffee is Associated with Reduced Risk of VTE
-
Sep 29, 2025, 05:06Sue Bacon on the Importance of Addressing Hospital-Acquired DVT and PE
-
Sep 24, 2025, 11:06Wolfgang Miesbach Reports Promising Results for New Subcutaneous von Willebrand Disease Therapy VGA039
-
Sep 23, 2025, 06:40Richard Buka: CSL Behring Have Announced a Collaboration with Dutch Biotech, VarmX
-
Sep 22, 2025, 07:10Aspirin Beyond the Heartโค Targeting PI3K-Altered Colorectal Cancer
-
Sep 22, 2025, 06:04ClearPlasma: A New Filter Technology to Enhance Clot Stability in Donated Plasma
-
Sep 29, 2025, 07:02Kambua Manundu: We Walked to Protest the Countless Lives of Women We Have Lost to Post Partum Hemorrhage
-
Sep 29, 2025, 06:41Ouma Oluga Unveiled Plans to Make Sickle Cell Screening Mandatory in Kenya at 80th UN General Assembly
-
Sep 29, 2025, 04:51Nathan Connell on Breakthrough Gene Therapy Advancing Care for People with Hemophilia
-
Sep 29, 2025, 04:28Emmeran Hauser: Fantastic to See First Results of Our Work in Europe
-
Sep 28, 2025, 10:33Cรดme Bommier: Burnout Is Common Among Hematology Professionals